NCT05833906 is a Phase 1 clinical trial of CKR-051 Dose 1 in Healthy, sponsored by CK Regeon Inc..

Who is sponsoring NCT05833906?

NCT05833906 is sponsored by CK Regeon Inc..

What drugs are being tested in NCT05833906?

Interventions in NCT05833906: CKR-051 Dose 1, CKR-051 Dose 2, CKR-051 Dose 3, CKR-051 Dose 4, Placebo.

Is NCT05833906 still recruiting?

NCT05833906 is currently completed. Last updated 19 January 2024.

Last reviewed 2024-01-19 · How we verify

NCT05833906

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety, Tolerability, and Pharmacokinetic Evaluations of CKR-051 After Transdermal Administration in Healthy Male Subjects

Completed Phase 1 Last updated 19 January 2024

What this trial tests

Phase 1 trial testing CKR-051 Dose 1 in Healthy in 52 participants. Completed in 8 January 2024.

Timeline

25 April 2023

Primary endpoint
8 January 2024

8 January 2024

Quick facts

Lead sponsor	CK Regeon Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	screening
Enrollment	52
Start date	25 April 2023
Primary completion	8 January 2024
Estimated completion	8 January 2024
Sites	1 location across South Korea

Drugs / interventions tested

CKR-051 Dose 1 — full drug profile →
CKR-051 Dose 2
CKR-051 Dose 3
CKR-051 Dose 4
Placebo

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

CK Regeon Inc. — full company profile →

Who can join

Adults 19 to 60, male only, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of CKR-051 in healthy participants. This study aiming to develop an agent for skin regeneration; potential treatments include acute and chronic wounds (c.f. Diabetic foot ulcers).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05833906 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CK Regeon Inc.
Last refreshed: 19 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05833906.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing